Druggable targets in cytokine release syndromes.
Carlos Luri-ReyIñaki EgurenIgnacio MatosPedro BerraondoIgnacio Melero BermejoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Bispecific T-cell engagers and CAR T-cells share the problem of eliciting acute systemic inflammation episodes known as Cytokine Release Syndrome (CRS). Knowledge on the sequential waves of cytokines that can be neutralized with clinically available agents is crucial to prevent or treat this condition without jeopardizing the antitumor therapeutic outcome.